UBS Group
RGLS

UBS Group’s Regulus Therapeutics RGLS Stock Holding History

UBS Group’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3
Closed -$7K – 8765
2015
Q1 		$7K Sell
3
-1
-25% -$2.17K ﹤0.01% 7915
2014
Q4 		$8K Buy
+4
New +$7.11K ﹤0.01% 8601

Other funds holding RGLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group's RGLS Position: Q2 2025 in Review

UBS Group sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 184,891 shares — an estimated $324K sold.

UBS Group first reported a position in RGLS in Q4 2014 and held it in 36 quarters. The position peaked at $324K in Q1 2025. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.

  • UBS Group reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • UBS Group sold 184,891 Regulus Therapeutics shares in Q2 2025, an estimated $324K.
  • UBS Group first reported a position in Regulus Therapeutics in Q4 2014 and held it in 36 quarters.
  • UBS Group's Regulus Therapeutics position peaked at $324K in Q1 2025.
  • 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.

Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.